Inhibitor Therapeutics, Inc. (INTI)
USD 0.07
(14.55%)
USD 0.07
(14.55%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.7 Million | 11.74 Million | -220.43 Thousand | -825.35 Thousand | -2.7 Million | -3.7 Million |
| Net Income | -3.02 Million | 12.1 Million | -298.63 Thousand | -1.05 Million | -2.73 Million | -4.55 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 13.78 Thousand | - | 37.99 Thousand | 228.86 Thousand | 269.92 Thousand | 543.09 Thousand |
| Change in working capital | 312.03 Thousand | 142.08 Thousand | 81.8 Thousand | 3711.00 | -242.28 Thousand | 298.86 Thousand |
| Other non-cash items | -383.59 Thousand | -507.71 Thousand | -41.6 Thousand | 264.6 Thousand | 540.34 Thousand | 543.09 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | 2.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -411 Thousand | 180 Thousand | 176 Thousand | 96.6 Thousand | 2.4 Million | 4.47 Million |
| Debt repayment | -411 Thousand | -180 Thousand | -176 Thousand | -96.6 Thousand | - | - |
| Dividends payments | - | - | - | -100.82 Thousand | -99.17 Thousand | -56.54 Thousand |
| Common Stock Repurchased | - | - | -176 Thousand | -96.6 Thousand | - | - |
| Common Stock Issuance | - | - | 200 Thousand | 200.54 Thousand | 99.94 Thousand | 3.96 Million |
| Other Financing Activities | -411 Thousand | 549.04 Thousand | 428.82 Thousand | 190.07 Thousand | 2.4 Million | 568.54 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 397.38 Thousand | 137.82 Thousand | 53.26 Thousand | -35.73 Thousand | -270.42 Thousand | -785.00 |
| Inventory | - | - | - | - | - | - |
| Other working capital | -85.34 Thousand | 4258.00 | 28.54 Thousand | 39.45 Thousand | 28.13 Thousand | 299.65 Thousand |
| Cash at beginning of period | 11.95 Million | 30.62 Thousand | 75.05 Thousand | 803.81 Thousand | 1.1 Million | 344.11 Thousand |
| Cash at end of period | 8.83 Million | 11.95 Million | 30.62 Thousand | 75.05 Thousand | 803.81 Thousand | 1.1 Million |
| Capital Expenditure | 2.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -3.11 Million | 11.92 Million | -44.43 Thousand | -728.75 Thousand | -304.89 Thousand | 764.6 Thousand |
| Free Cash Flow | -2.7 Million | 11.74 Million | -220.43 Thousand | -825.35 Thousand | -2.7 Million | -3.7 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -501.68 Thousand | -684.71 Thousand | -1.16 Million | -3.02 Million | -664.76 Thousand | -654.52 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1160.00 | 39.09 Thousand | 12.25 Thousand | 13.78 Thousand | 1534.00 | 12.25 Thousand |
| Change in working capital | -82.54 Thousand | -512.47 Thousand | 469.55 Thousand | 312.03 Thousand | 100.51 Thousand | -40.34 Thousand |
| Other non-cash items | 121.48 Thousand | 548.4 Thousand | -508.72 Thousand | -383.59 Thousand | -111.04 Thousand | 12.25 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | -411 Thousand | - | - |
| Debt repayment | - | - | -411 Thousand | -411 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | -410.58 Thousand | -411 Thousand | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -120.32 Thousand | -509.31 Thousand | 508.72 Thousand | 397.38 Thousand | 112.58 Thousand | -34.58 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 37.77 Thousand | -3156.00 | -39.17 Thousand | -85.34 Thousand | -12.06 Thousand | -5759.00 |
| Cash at beginning of period | 7.68 Million | 8.83 Million | 9.53 Million | 11.95 Million | 10.1 Million | 10.78 Million |
| Cash at end of period | 7.09 Million | 7.68 Million | 8.83 Million | 8.83 Million | 9.53 Million | 10.1 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -583.07 Thousand | -1.15 Million | -697.7 Thousand | -3.11 Million | -562.7 Thousand | -682.61 Thousand |
| Free Cash Flow | -583.07 Thousand | -1.15 Million | -697.7 Thousand | -2.7 Million | -562.7 Thousand | -682.61 Thousand |
UTKARSHBNK
1538
PURPLE
TTNMF
IRTC
EMDV